530 related articles for article (PubMed ID: 7947097)
1. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.
Smith PJ; Souès S; Gottlieb T; Falk SJ; Watson JV; Osborne RJ; Bleehen NM
Br J Cancer; 1994 Nov; 70(5):914-21. PubMed ID: 7947097
[TBL] [Abstract][Full Text] [Related]
2. Differential sensitivity to etoposide (VP-16)-induced S phase delay in a panel of small-cell lung carcinoma cell lines with G1/S phase checkpoint dysfunction.
Soués S; Wiltshire M; Smith PJ
Cancer Chemother Pharmacol; 2001; 47(2):133-40. PubMed ID: 11269739
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
[TBL] [Abstract][Full Text] [Related]
4. Etoposide induces G2/M arrest and apoptosis in neural progenitor cells via DNA damage and an ATM/p53-related pathway.
Nam C; Doi K; Nakayama H
Histol Histopathol; 2010 Apr; 25(4):485-93. PubMed ID: 20183801
[TBL] [Abstract][Full Text] [Related]
5. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
Yu Q; Mirski SE; Sparks KE; Cole SP
Biochemistry; 1997 May; 36(19):5868-77. PubMed ID: 9153428
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle checkpoint evasion and protracted cell cycle arrest in X-irradiated small-cell lung carcinoma cells.
Smith PJ; Wiltshire M; Chin SF; Rabbitts P; Souès S
Int J Radiat Biol; 1999 Sep; 75(9):1137-47. PubMed ID: 10528922
[TBL] [Abstract][Full Text] [Related]
9. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response.
Guinee DG; Holden JA; Benfield JR; Woodward ML; Przygodzki RM; Fishback NF; Koss MN; Travis WD
Cancer; 1996 Aug; 78(4):729-35. PubMed ID: 8756364
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
11. Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line.
Evans CD; Mirski SE; Danks MK; Cole SP
Cancer Chemother Pharmacol; 1994; 34(3):242-8. PubMed ID: 8004758
[TBL] [Abstract][Full Text] [Related]
12. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
13. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
[TBL] [Abstract][Full Text] [Related]
14. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
Fan S; el-Deiry WS; Bae I; Freeman J; Jondle D; Bhatia K; Fornace AJ; Magrath I; Kohn KW; O'Connor PM
Cancer Res; 1994 Nov; 54(22):5824-30. PubMed ID: 7954409
[TBL] [Abstract][Full Text] [Related]
15. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells.
Traganos F; Ardelt B; Halko N; Bruno S; Darzynkiewicz Z
Cancer Res; 1992 Nov; 52(22):6200-8. PubMed ID: 1330289
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
[TBL] [Abstract][Full Text] [Related]
17. Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells.
Chiu CC; Li CH; Ung MW; Fuh TS; Chen WL; Fang K
Cancer Lett; 2005 Jun; 223(2):249-58. PubMed ID: 15896459
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
Nitiss JL; Wang JC
Mol Pharmacol; 1996 Nov; 50(5):1095-102. PubMed ID: 8913340
[TBL] [Abstract][Full Text] [Related]
20. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.
Takano H; Kohno K; Ono M; Uchida Y; Kuwano M
Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
